You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞通窩輪》【瑞通認股證牛熊證】恆指再試兩萬六、投資者好淡分歧 京東彈2%挑戰廿天線、資金追好倉 恆指牛55536 熊56122/ 京東購22991 沽18178 牛54192 熊58714
阿思達克 12-23 11:32
美國國會通過新一輪紓困方案,但投資者繼續憂慮全球疫情發展。美股隔晚個別發展,道指收報30015點,跌200點(或0.6%)。納指則創收市新高。恆指昨收報26119點,跌187點(或0.7%),盤中一度失守26000點關,錄三連跌。今早跌數十點,再試26000點水平。恆指好倉(牛證及認購權證)昨淨流入逾6700萬港元(下同),恆指淡倉(熊證及認沽權證)同日淨流出近2800萬元,反映投資者看好大市將見技術性反彈。昨日恆指牛證街貨重貨區為收回價25900至25999點,而熊證街貨重貨區為收回價27300至27399點。

京東健康(06618)上市後持續刷出新高,不過母企京東集團(09618)未受帶動,昨儘管曾升2.5%至321.4元,最終全日升幅收窄至0.5%,報315.2元,10天線得而復失,月內續呈反覆向下走勢。京東旗下京東金融近日下架互聯網存款相關服務,並作出人員變動。另外,內地針對社區團購出台新規,禁低價傾銷、限制競爭等。京東今早回升逾1%,高位重上320元。昨分別有逾270萬元和逾60萬元淨流出其好倉和淡倉。

藥明生物(02269)旗下附屬斥資逾14億元收購德國工廠設施資產,以提升新冠疫苗及其他生物藥的產能,加上內地醫保談判落幕,政策不明朗因素消除,藥明連日強勢破頂,昨最高見94元創新高,收報92.2元,升1.7%,六個交易日累漲近18%。股份今早稍為回落,下試91元。昨有逾10萬元淨流出其好倉。

A股昨午後跌勢轉急,加上據報銀保監要求險企排查明年滿期給付與退保風險,拖累內險股表現。中國平安(02318)昨先升後回,倒跌1.8%收市,報91.5元,處10天和20天線以下。今早略回,徘徊在92元以下。昨有逾330萬元淨流入其好倉,淡倉同日則錄逾140萬元淨流出。

全國人大法制工作委員會表明修訂《反壟斷法》是明年重點工作。另外,恆指公司就優化恆生指數向市場諮詢,當中包括現時權重限制於5%的同股不同權股份有機會獲提升權重。美團(03690)昨收跌0.7%於276.2元,盤中續受制於下移中的10天線(現處282元水平)。今早低走,曾跌至274元。超過2800萬元在昨日淨流出其好倉,淡倉同日則有逾20萬元淨流入。

瑞通相關認股證之選擇:

京東輕微價外、中短期購22991,行使價:368.888元,2021年6月到期,實際槓桿:5倍

京東貼價、短期沽18178,行使價:310.99元,2021年3月到期,實際槓桿:6.2倍

平保輕微價外、中年期購12998,行使價:97.8元,2021年7月到期,實際槓桿:8.4倍

平保輕微價外、中短期沽19664,行使價:82.1元,2021年6月到期,實際槓桿:7.2倍

美團輕微價外、短期購29263,行使價:299.08元,2021年2月到期,實際槓桿:8倍

美團貼價、中短期沽18034,行使價:264.88元,2021年6月到期,實際槓桿:3倍

瑞通相關牛熊證之選擇:

恆指牛證55536,收回價:25560點,槓桿比率:38倍

恆指熊證56122,收回價:26710點,槓桿比率:36倍

京東牛證54192,收回價:299.1元,槓桿比率:9.2倍

京東熊證58714,收回價:338.88元,槓桿比率:11.8倍

藥明牛證58811,收回價:73.1元,槓桿比率:4.1倍

平保牛證60008,收回價:85.38元,槓桿比率:13倍

平保熊證55528,收回價:101.88元,槓桿比率:6.8倍

美團牛證56139,收回價:264元,槓桿比率:12倍

美團熊證68120,收回價:297.18元,槓桿比率:14倍

重要風險通知

本結構性產品並無抵押品。

結構性產品之價格一般可急升亦可急跌,有可能損失結構性產品之全部或重大部分購買價,閣下對此應有所準備。

閣下投資前應了解產品風險,如有需要應諮詢專業建議。~

重要聲明:

以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account